Back to Publications

Abstract 22 | NASH-TAG 2021

Authors: Michael J. Hamill, Nadine Daou, Arianna Nitzel, Lorena Pantano, Margaret Koziel, and Manu V. Chakravarthy


  • Recent advances in network biology have assisted in unraveling the complex pathophysiological processes underlying nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) and cirrhosis1
  • The close inter-connectivity of the contributory molecular pathways suggests that effective pharmacotherapy may require a coordinated multitargeted approach
  • Per this premise, endogenous metabolic modulators (EMMs) have emerged as a core class of signaling agents and metabolic substrates with the potential to simultaneously impact multiple metabolic and fibroinflammatory pathways in NASH1
  • EMMs consisting of amino acids are intrinsically fundamental to core NASH pathways2